Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors

11 Feb 2016

Abstract excerpt

RAD52 is a member of the homologous recombination (HR) pathway that is important for maintenance of genome integrity. While single RAD52 mutations show no significant phenotype in mammals, their combination with mutations in genes that cause hereditary breast cancer and ovarian cancer like BRCA1, BRCA2, PALB2 and RAD51C are lethal. Consequently, RAD52 may represent an important target for cancer therapy. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26873923
DOI: 10.1093/nar/gkw087

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitorsPMID 26873923Read ↗

Identification of small molecule inhibitors of RAD52 for breast cancer therapy: in silico approachSemantic proximity Read ↗

New RAD51 Inhibitors to Target Homologous Recombination in Human CellsSemantic proximity Read ↗

Molecular Pathways: Understanding the Role of Rad52 in Homologous Recombination for Therapeutic AdvancementSemantic proximity Read ↗

A Small Molecule Inhibitor of Human RAD51 Potentiates Breast Cancer Cell Killing by Therapeutic Agents in Mouse XenograftsSemantic proximity Read ↗

RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer TherapiesSemantic proximity Read ↗

Reappearance from Obscurity: Mammalian Rad52 in Homologous RecombinationSemantic proximity Read ↗

A moving target for drug discovery: Structure activity relationship and many genome (de)stabilizing functions of the RAD52 proteinSemantic proximity Read ↗

Novel structural insights on full-length human RAD52: Cryo-EM and beyondSemantic proximity Read ↗

Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells.Semantic proximity Read ↗

Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.Semantic proximity Read ↗

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor CellsSemantic proximity Read ↗

Emerging Roles of RAD52 in Genome MaintenanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.